Sec Form 4 Filing - Santel Donald J @ Oyster Point Pharma, Inc. - 2021-07-30

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Santel Donald J 2. Issuer Name and Ticker or Trading Symbol Oyster Point Pharma, Inc. [ OYST] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109 3. Date of Earliest Transaction (MM/DD/YY) 07/30/2021 (Street) PRINCETON, NJ08540 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/30/2021 A( 1 ) 6,937 ( 2 ) A $ 0 6,937 D Common Stock 07/30/2021 A( 1 ) 3,177 ( 3 ) A $ 0 10,114 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 14.25 07/30/2021 A 10,405 ( 4 ) 07/30/2021 Common Stock 10,405 $ 0 10,405 D Stock Option (Right to Buy) $ 14.25 07/30/2021 A 4,765 ( 5 ) 07/30/2021 Common Stock 4,765 $ 0 4,765 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Santel Donald J C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON, NJ08540 X Signatures /s/ Brandon Fenn, Attorney-in-Fact 08/03/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. ( 2 )These RSUs will vest over three years (on the same day of the month as the grant date) with one-third (1/3) vesting annually, in each case subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2019 Equity Incentive Plan (the "Plan")) through each such date. ( 3 )These RSUs will vest on June 7, 2022, but will vest fully on the date of the Company's next annual meeting of stockholders held after the date of grant if not fully vested on such date, subject to the Reporting Person continuing to be a Service Provider through such date. ( 4 )One-third (1/3) of the shares subject to the option shall vest on the 12 month anniversary of the grant date and the remainder will vest at one-twentyfourth (1/24th) per month thereafter (on the same day of the month as the grant date), subject to the Reporting Person continuing to be a Service Provider through each such date. ( 5 )One-eleventh (1/11th) of the Shares subject to the Option shall vest monthly beginning on August 7, 2021 and on the same day monthly thereafter, but will vest fully on the date of the Issuer's next annual meeting of stockholders held after the date of grant if not fully vested on such date, subject to the Reporting Person continuing to be a Service Provider through each such date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.